Johnson Investment Counsel Inc. Increases Stock Position in Charles River Laboratories International, Inc. $CRL

Johnson Investment Counsel Inc. boosted its position in Charles River Laboratories International, Inc. (NYSE:CRLFree Report) by 5.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,570 shares of the medical research company’s stock after purchasing an additional 1,045 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Charles River Laboratories International were worth $3,121,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of CRL. Brooklyn Investment Group lifted its stake in Charles River Laboratories International by 93.5% in the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after purchasing an additional 86 shares in the last quarter. Cromwell Holdings LLC lifted its stake in Charles River Laboratories International by 542.9% in the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after purchasing an additional 152 shares in the last quarter. HM Payson & Co. purchased a new stake in Charles River Laboratories International in the 1st quarter worth approximately $31,000. Family Legacy Financial Solutions LLC purchased a new stake in Charles River Laboratories International in the 2nd quarter worth approximately $71,000. Finally, ORG Wealth Partners LLC lifted its stake in Charles River Laboratories International by 49.8% in the 2nd quarter. ORG Wealth Partners LLC now owns 496 shares of the medical research company’s stock worth $77,000 after purchasing an additional 165 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on CRL. Evercore ISI increased their target price on shares of Charles River Laboratories International from $190.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, October 3rd. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and raised their price objective for the company from $142.00 to $195.00 in a research report on Tuesday, September 9th. JPMorgan Chase & Co. raised their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. William Blair upgraded shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research report on Monday, October 6th. Finally, Barclays upgraded shares of Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $165.00 to $195.00 in a research report on Thursday, October 2nd. Eight equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and an average target price of $179.93.

Check Out Our Latest Report on CRL

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president owned 24,116 shares of the company’s stock, valued at $3,800,681.60. This trade represents a 3.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Price Performance

CRL stock opened at $167.17 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $230.02. The firm’s fifty day moving average is $159.23 and its 200 day moving average is $147.48. The firm has a market cap of $8.23 billion, a P/E ratio of -125.69, a P/E/G ratio of 4.47 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRLGet Free Report) last released its earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating the consensus estimate of $2.50 by $0.62. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.80 EPS. Research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

(Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Recommended Stories

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLFree Report).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.